The Conversation (0)
Intellipharmaceutics International (Nasdaq:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, today provided an operational update on its plans and projected timelines for the 2018 year. As quoted in the update: “2017 marked a series of important accomplishments that we believe will …
Intellipharmaceutics International (Nasdaq:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, today provided an operational update on its plans and projected timelines for the 2018 year.
As quoted in the update:
“2017 marked a series of important accomplishments that we believe will set the stage for growth in 2018 and beyond,” commented Dr. Isa Odidi, Chief Executive Officer and co-founder of Intellipharmaceutics. “We continue to be optimistic about our abuse-deterrent oxycodone hydrochloride extended release tablets (Oxycodone ER) product candidate. The complete response letter (CRL) from the FDA in our view was favorable as it clarified concerns expressed by the FDA Advisory Committees and the path for resubmission of the application. We remain confident in the potential commercial opportunity for Oxycodone ER, and our other drug development and commercialization initiatives also remain on track. We believe that our product portfolio positions us well for growth and look forward to further executing on our plans into 2018.”
